Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation-positive NSCLC: An interim analysis of the ARIA study

被引：0
|
作者：
Wu, L. [1 ,2 ]
Li, J. [3 ]
Xu, C. [4 ,5 ]
Biswas, B. [6 ]
Tang, K. [7 ]
Wang, H. [8 ,9 ]
Liu, Z. [10 ]
Batra, U. [11 ]
Ho, G. F. [12 ]
Low, S. H. J. [13 ]
Lu, Y. [14 ]
Zhao, M. [15 ]
Tho, L. M. [16 ]
Zhao, J. [17 ]
He, S. [18 ]
Huang, J. [19 ]
Tang, X. [20 ]
Wong, C. H. [21 ]
Wu, Y-L. [4 ,5 ]
机构：
[1] Cent South Univ, Dept Med Oncol, Hunan Canc Hosp, Changsha, Peoples R China
[2] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, China Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[4] Guangdong Prov Peoples Hosp, Lung Canc Inst, Guangzhou, Peoples R China
[5] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India
[7] Sun Yat Sen Univ, Resp & Crit Care Med Dept, Affiliated Hosp 1, Guangzhou, Peoples R China
[8] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] First Hosp Jilin Univ, Dept Oncol Ctr, Changchun, Peoples R China
[11] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India
[12] Univ Malaya, Dept Clin Oncol, Med Ctr, Kuala Lumpur, Malaysia
[13] Pantai Hosp, Oncol & Radiotherapy, Kuala Lumpur, Malaysia
[14] Sichuan Univ, West China Sch Clin Med, West China Hosp, Oncol, Chengdu, Peoples R China
[15] China Med Univ, Dept Oncol, Hosp 1, Shenyang, Peoples R China
[16] Beacon Hosp, Dept Clin Oncol, Petaling Jaya, Malaysia
[17] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Thorac Oncol, Minist Educ, Beijing, Peoples R China
[18] Pfizer Inc, Clin Dev, Shanghai, Peoples R China
[19] Pfizer China Res & Dev Co Ltd, Clin Data Qual Dev China, Shanghai, Peoples R China
[20] Pfizer Inc, Pfizer GB & DM, CHN Stat, Shanghai, Peoples R China
[21] Pfizer Pte Ltd, Med Affairs, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2370
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1337P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
    Gwo-Fuang Ho
    Chee-Shee Chai
    Adlinda Alip
    Mohd Ibrahim A. Wahid
    Matin Mellor Abdullah
    Yoke-Ching Foo
    Soon-Hin How
    Adel Zaatar
    Kai-Seng Lam
    Kin-Wah Leong
    John-Seng-Hooi Low
    Mastura Md Yusof
    Erica Chai-Yong Lee
    Yok-Yong Toh
    Chong-Kin Liam
    BMC Cancer, 19
  • [32] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
    Ho, Gwo-Fuang
    Chai, Chee-Shee
    Alip, Adlinda
    Wahid, Mohd Ibrahim A.
    Abdullah, Matin Mellor
    Foo, Yoke-Ching
    How, Soon-Hin
    Zaatar, Adel
    Lam, Kai-Seng
    Leong, Kin-Wah
    Low, John-Seng-Hooi
    Yusof, Mastura Md
    Lee, Erica Chai-Yong
    Toh, Yok-Yong
    Liam, Chong-Kin
    BMC CANCER, 2019, 19 (01)
  • [33] PANORAMA - Real world molecular testing, treatment patterns, and clinical outcomes in patients with EGFR mutation-positive locally advanced or advanced NSCLC
    Griesinger, F.
    Buettner, R.
    Deppermann, K. -M.
    Reinmuth, N.
    Schuette, W.
    Thomas, M.
    Bergner, S.
    Schumann, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 248 - +
  • [34] Durvalumab plus chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
    Cho, B. C.
    Ahn, M. J.
    Baik, C.
    Garcia, R.
    Goldman, J. W.
    Kim, S-W.
    Lee, J. S.
    Nishio, M.
    Ponce, S.
    Salgia, R.
    Teraoka, S.
    Yoshida, T.
    Yu, H. A.
    Ambrose, H.
    Cosaert, J.
    Hartmaier, R.
    Maidment, J.
    Pluta, M.
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2022, 33 : S34 - S35
  • [35] A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
    Chihara, Yusuke
    Takeda, Takayuki
    Goto, Yasuhiro
    Nakamura, Yoichi
    Tsuchiya-Kawano, Yuko
    Nakao, Akira
    Onoi, Keisuke
    Hibino, Makoto
    Fukuda, Minoru
    Honda, Ryoichi
    Yamada, Takahiro
    Taniguchi, Ryusuke
    Sakamoto, Sinjiro
    Date, Koji
    Nagashima, Seiji
    Tanzawa, Shigeru
    Minato, Koichi
    Nakatani, Koichi
    Izumi, Miiru
    Shimose, Takayuki
    Kishimoto, Junji
    Uchino, Junji
    Takayama, Koichi
    ONCOLOGIST, 2022, 27 (11): : 903 - E834
  • [36] Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
    Choi, Juwhan
    Choi, Chang Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Lee, Sung Yong
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2275 - 2282
  • [37] Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Real-World-Data on First-Line Therapy with Osimertinib in Patients with advanced EGFR-mutated NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Shenolikar, R.
    Shaw, S.
    PNEUMOLOGIE, 2021, 75 : S11 - S11
  • [39] Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study.
    Dechow, Tobias Nicolaas
    Riera-Knorrenschild, Jorge
    Hackanson, Bjorn
    von Weikersthal, Ludwig Fischer
    Schulz, Holger
    Chiabudini, Marco
    Timm, Barbara
    Zerbes, Ralf
    Potthoff, Karin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Real world molecular testing in patients with EGFR mutation-positive locally advanced or advanced NSCLC in routine practice in Germany - Interim results of the clinical registry PANORAMA
    Griesinger, F.
    Buettner, R.
    Deppermann, K-M
    Reinmuth, N.
    Schuette, W.
    Thomas, M.
    Wroblewski, M.
    Schumann, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 249 - 249
12345